Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 10/20 | 0.60 |
| ▸ | CDK9 | P50750 | 10/20 | 0.60 |
| ▸ | ALK | Q9UM73 | 10/20 | 0.54 |
| ▸ | INSR | P06213 | 6/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | ROS1 | P08922 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375643 | 0.89 | ALK (0.67) | CDK7CDK9ALKINSRROS1 | |
| SCHEMBL29666260 | 0.89 | ALK (0.67) | CDK7CDK9ALKINSRROS1 | |
| SCHEMBL18627483 | 0.87 | CDK9 (0.62) | CDK7CDK9ALKINSRKCNH2 | |
| SCHEMBL28449568 | 0.86 | CDK7 (0.60) | CDK7CDK9ALKROS1AURKA | |
| SCHEMBL18843572 | 0.86 | CDK7 (0.54) | CDK7CDK9ALKROS1AURKA | |
| SCHEMBL29214361 | 0.86 | CDK7 (0.60) | CDK7CDK9ALKROS1AURKA | |
| SCHEMBL18843571 | 0.84 | ALK (0.66) | CDK7CDK9ALKINSRIGF1R | |
| SCHEMBL25139977 | 0.83 | ALK (0.51) | CDK7CDK9ALKINSRROS1 | |
| SCHEMBL1491763 | 0.83 | ALK (0.52) | CDK7CDK9ALKINSRROS1 | |
| SCHEMBL30978775 | 0.82 | CDK7 (0.66) | CDK7CDK9ALKINSRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
| EP-3210609-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| WO-2017041771-A1 | PROCESS FOR THE PREPARATION OF CERITINIB USING \"IN SITU\" PREPARED 5-METHYL-2-(1 -METHYLETHOXY)-4-(4-PIPERIDINYL)-BENZENAMINE MONOHYDROCHLORIDE (1 :1 ) AS AN INTERMEDIATE | ZENTIVA, K.S. (CZ) | 2017-03-16 | — | — | WO | disclosed |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | ARIAD PHARMA INC (US) | 2016-12-29 | — | — | US | disclosed |
| WO-2016199020-A1 | PROCESS FOR PREPARATION OF CERITINIB | DR. REDDY'S LABORATORIES LIMITED (IN) | 2016-12-15 | — | — | WO | disclosed |
| EP-3012249-A1 | COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| EP-3012249-A1 | COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-8039479-B2 | Such as 6-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]-pyrimidin-2-ylamino}-5-isopropoxy-2-piperidin-4-yl-2,3-dihydro-isoindol-1-one; tumors, cancer; inhibition of anaplastic lymphoma, focal adhesion, zeta chain associated protein 70 and/or insulin like growth factor | IRM LLC (BM) | 2011-10-18 | — | — | US | disclosed |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| EP-2311807-A1 | Compounds and composition as protein kinase inhibitors | IRM LLC (BM) | 2011-04-20 | — | — | EP | disclosed |
| EP-2300013-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD Pharmaceuticals, Inc (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009143389-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | CDK7 104/4885CDK9 60/4885ALK 256/4885 |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | CDK7 399/4885CDK9 431/4885ALK 23/4885 |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | MAP3K6, PIK3CA, MAP3K20 | CDK7 96/4885CDK9 59/4885ALK 265/4885 |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | CDK7 399/4885CDK9 431/4885ALK 23/4885 |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | CDK7 104/4885CDK9 60/4885ALK 256/4885 |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | CDK7 104/4885CDK9 60/4885ALK 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.